|
|
|
| About Hodgson Russ | Practice Areas | Attorneys & Other Professionals | News & Seminars | Careers | Offices |
 |
|
Anti-Discrimination in Employment: Retaliation Gets Personal Antitrust Alert: HSR Size of Deal Thresholds Raised Benefits Alert - Deferred Compensation Under 409A: Action Items New law increases strictness and severity of publication requirements for LLEs and LPs Tax Alert: Corporate Inversions—Recent US Tax Developments Tax avoidance transactions and reporting requirements in New York State and Local Tax Client Alert - Municipal Bonds New York Enacts State False Claims Act: Implications Beyond Medicaid New DHS Rules Regarding Employer Handling of Social Security No-Match Lette United States Foreign Corrupt Practices Act |
Home > News & Seminars > Alerts > United States Foreign Corrupt Practices Act United States Foreign Corrupt Practices Act
On February 12, 2007, Johnson & Johnson acknowledged that it had disclosed to the Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) “that subsidiaries outside the United States are believed to have made improper payments in connection with the sale of medical devices in two small-market countries.” That announcement highlights the risks for the medical device industry of violating the Foreign Corrupt Practices Act (FCPA) and reflects a more pervasive trend of increased FCPA enforcement. |
|
|
||
|
|
|
|
|
